Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Transplant Proc ; 43(5): 1847-52, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21693288

ABSTRACT

BACKGROUND: Everolimus is a proliferation-signal inhibitor which was introduced for heart transplant recipients in 2004. To date, there are only sparse data about long-term calcineurin inhibitor (CNI)-free immunosuppression using everolimus. METHODS: After heart transplantation, patients receiving everolimus were consecutively enrolled. Reasons for switching to everolimus were side effects of CNI immunosuppression, such as deterioration of kidney function and recurrent rejection episodes. All 60 patients underwent standardized switching protocols, 42 patients completed 24-month follow-up. Blood was sampled for lipid status, renal function, routine controls, and levels of immunosuppressive agents. On days 0, 14, and 28, and then every 3 months, echocardiography and physical examination were performed. RESULTS: After switching to everolimus, most patients recovered from the side effects. Renal function improved significantly after 24 months (creatinine, 2.1 ± 0.6 vs 1.8 ± 1 mg/dL; P < .001; creatinine clearance, 41.8 ± 22 vs 48.6 ± 21.8 mL/min; P < .001). Median blood pressure increased from 120.0/75.0 mm Hg at baseline to 123.8/80.0 mm Hg at month 24 (P values .008 and .003 for systolic and diastolic pressures, respectively). Tremor, peripheral edema, hirsutism, and gingival hyperplasia markedly improved. Levels of interleukin-6 were stable between baseline and 24-month levels. Temporary adverse events occurred in 8 patients [13.3%: interstitial pneumonia (n = 2), skin disorders (n = 2); reactivated hepatitis B (n = 1), and fever of unknown origin (n = 3)]. CONCLUSION: CNI-free immunosuppression using everolimus is safe, with excellent efficacy in maintenance of heart transplant recipients. Arterial hypertension and renal function significantly improved. CNI-induced side effects, such as tremor, peripheral edema, hirsutism, and gingival hyperplasia, markedly improved in most patients.


Subject(s)
Calcineurin Inhibitors , Heart Transplantation , Immunosuppressive Agents/administration & dosage , Sirolimus/analogs & derivatives , Aged , Blood Pressure , Creatinine/blood , Creatinine/urine , Everolimus , Female , Follow-Up Studies , Germany , Hospitals, University , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Prospective Studies , Sirolimus/administration & dosage
3.
Transplant Proc ; 40(4): 953-5, 2008 May.
Article in English | MEDLINE | ID: mdl-18555088

ABSTRACT

Mycophenolic acid (MPA) is an effective immunosuppressive treatment for renal transplant recipients, but its effective use and best practice are not established in cardiac transplantation. This multicenter, single-blind, randomized, parallel group clinical trial prospectively evaluated the therapeutic equivalence of enteric-coated mycophenolate-sodium (EC-MPS) versus mycophenolate mofetil (MMF) in combination with cyclosporine (CyA) and steroids as determined by the primary objective of treatment efficacy during the first 6 months of treatment in 154 de novo heart transplant recipients. Both groups received equivalent doses of MPA, either 720 mg b.i.d EC-MPS or 1000 mg b.i.d MMF. EC-MPS showed a comparable efficacy and safety profile compared with MMF with significantly less dose reduction. Treatment failure occurred in 57.7% and 60.5% with EC-MPS and MMF, respectively, EC-MPS was therapeutically equivalent to MMF in cardiac transplantation.


Subject(s)
Heart Transplantation/immunology , Immunosuppressive Agents/therapeutic use , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Adolescent , Adult , Aged , Cyclosporine/therapeutic use , Drug Therapy, Combination , Female , Graft Rejection/epidemiology , Humans , Immunosuppressive Agents/pharmacokinetics , Male , Middle Aged , Mycophenolic Acid/pharmacokinetics , Prednisone/therapeutic use , Single-Blind Method , Tablets, Enteric-Coated , Treatment Failure , Treatment Outcome
4.
Thorac Cardiovasc Surg ; 55(4): 264-7, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17546561

ABSTRACT

OBJECTIVES: During the past 2 decades, cardiac surgery has developed into a high-tech field. Increasing numbers of urgent surgical procedures mean that the time interval from diagnosis to surgical treatment must become ever shorter. Optimizing inconvenient and slow processes such as postal correspondence by using internet services is therefore mandatory in current cardiosurgical practice, and this includes the electronic transfer of patient data and diagnostic imaging material [12]. This study focuses on the internet connection of several cardiac referral centers to a cardiosurgical institution. METHODS: Eleven cath lab centers were connected to a cardiosurgical center by internet. Auser program was especially developed to optimize connecting processes with the department. Data conversion was based on HL7 codes and angiograms were based on CD-ROM mediums and the DICOM standard. An online registration based on the HL7 communications standard was provided. RESULTS: All cath lab centers were successfully connected to the cardiosurgical institution. Angiography data were transmitted within 30 +/- 15minutes. The time interval from diagnosis to decision for surgery decreased from 36 +/- 13 hours to 1 +/- 0.5 hours (p = 0.01). Urgent or emergent surgery could be provided after 18 +/- 19 hours, compared to 56 +/- 35 hours before (p = 0.02). CONCLUSION: Special programs transmitting data via the internet significantly reduces the time interval from diagnosis to surgical treatment. Standardizing data transmitting processes from referral centers markedly optimizes cardiological and cardiosurgical treatments and could thereby improve survival rates and reduce costs.


Subject(s)
Cardiac Catheterization , Cardiology/organization & administration , Computer Communication Networks , Telemedicine , Computer Communication Networks/standards , Humans , Internet , Thoracic Surgery
5.
J Heart Lung Transplant ; 25(5): 596-602, 2006 May.
Article in English | MEDLINE | ID: mdl-16678040

ABSTRACT

BACKGROUND: Aminoterminal B-type pro-natriuretic peptide (NT-proBNP) is a reliable indicator of heart failure severity. Levels of NT-proBNP are markedly increased in patients with coronary artery disease (CAD) and severely impaired left ventricular (LV) function. The aim of our study was to assess the impact of NT-proBNP levels after high-risk coronary artery bypass grafting (CABG) with regard to recovery potential. METHODS: Between 1998 and 2004, 121 patients with CAD and severely impaired LV function, who were undergoing CABG, were investigated. Their mean age was 64 +/- 11 years. All patients were in New York Heart Association (NYHA) Class III/IV status; LV ejection fraction (EF) was 20 +/- 6%. All survivors underwent follow-up (59 +/- 34 months) spiroergometric, electrocardiographic (ECG) and echocardiographic assessment and were tested for routine blood controls and NT-proBNP levels (Roche, Mannheim, Germany). RESULTS: The survival rate after 8 years was 70%. All survivors received follow-up assessment. Among survivors the median NT-proBNP level at follow-up was 896 (521 to 1,687) pg/ml. The maximum oxygen uptake was 14.6 +/- 4.9 ml/min/kg, and EF increased to 42% at follow-up among all survivors. On dichotomizing survivors into two groups with NT-proBNP levels above and below the median, the post-operative body mass index was significantly higher in the high NT-proBNP group (p = 0.036). EF (p = 0.028) and NYHA classification (p < 0.05) improved significantly in both groups, with a tendency toward higher EF in the low NT-proBNP group. CONCLUSIONS: Patients undergoing a high-risk CABG procedure have a survival rate comparable to heart transplantation patients and show a potential for clinical and myocardial recovery. NT-proBNP use a useful marker for recovery after a high-risk CABG procedure, with significant correlation with clinical parameters.


Subject(s)
Biomarkers/blood , Coronary Artery Bypass , Myocardial Ischemia/surgery , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/surgery , Aged , Comorbidity , Coronary Artery Bypass/mortality , Exercise Test , Female , Humans , Male , Middle Aged , Multivariate Analysis , Myocardial Ischemia/blood , Myocardial Ischemia/epidemiology , Postoperative Period , Recovery of Function , Spirometry , Survival Analysis , Ventricular Dysfunction, Left/epidemiology
6.
J Cardiovasc Surg (Torino) ; 46(5): 509-14, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16278643

ABSTRACT

Nowadays, radial artery grafts play a significant role in coronary artery revascularization, however, harvesting techniques are not standardized. We developed various surgical techniques for radial artery harvesting considering the anatomic landmarks of the foramen, including conventional surgery (with scissors and clips) and procedures with ultrasonic scalpel and retrieving the radial artery graft in a pedicle or in a skeletonized manner.


Subject(s)
Radial Artery/surgery , Tissue and Organ Harvesting/methods , Coronary Artery Bypass , Dissection/instrumentation , Dissection/methods , Humans , Papaverine , Tissue and Organ Harvesting/instrumentation
8.
Thorac Cardiovasc Surg ; 53(2): 85-92, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15786006

ABSTRACT

OBJECTIVE: We sought to examine our management and the outcomes of cardiothoracic procedures after heart and heart lung transplantation. METHODS: We performed a retrospective review of cardiothoracic surgical procedures carried out between 1990 and 2004 in patients who had previously undergone heart or heart-lung transplantation at our institution. RESULTS: Twenty-one out of 340 patients (6.2 %) were identified. Cardiothoracic surgery was performed 44.4 +/- 33 months (range 1 - 115 months) after transplantation. Predominant types of surgery were coronary artery bypass grafting due to allograft vasculopathy (n = 5), aortic surgery due to acute dissection (n = 3), biventricular assist device implantation due to acute rejection (n = 1), tricuspid valve repair (n = 1), multiple cardiac surgical procedures including coronary artery bypass grafting, retransplantation, and tricuspid valve replacement (n = 2), explantation of a functionless heterotopic transplanted heart (n = 1). Lung surgery was performed in six patients due to pneumonia (n = 2), primary lung carcinoma (n = 3), lung torsion following heart-lung transplantation (n = 1). All patients underwent either lobectomy or segmental lung resection. Single lung retransplantation (n = 2) after prior heart-lung transplantation due to bronchiolitis obliterans was performed. In one patient a pneumonectomy (n = 1) due to severe chronic rejection of the contralateral lung was performed. Six subsequent deaths after cardiothoracic procedures were recorded after 1, 4, 78, 163, 205, and 730 days, respectively. Causes of death were advanced carcinoma (n = 1), multi-organ failure due to sepsis (n = 2), sudden heart death (n = 2), and advanced heart failure (n = 1). Fifteen out of 21 patients having undergone cardiothoracic procedures (71.4 %) survived the observation period of 56.6 +/- 34 months (range 1 - 114). CONCLUSIONS: Reasons for cardiothoracic procedures after prior heart or heart-lung transplantation were allograft vasculopathy, aortic dissections years after transplantation, chronic rejection, and either lung infections or malignancies. Surgical repair can be performed with an acceptable operative risk and good long-term survival rates.


Subject(s)
Coronary Artery Bypass , Heart Transplantation , Heart-Lung Transplantation , Lung Diseases/surgery , Pneumonectomy , Vascular Diseases/surgery , Cardiac Surgical Procedures , Female , Humans , Male , Middle Aged , Postoperative Complications/surgery , Retrospective Studies , Survival Rate , Thoracic Surgical Procedures , Time Factors , Tomography, X-Ray Computed
9.
Thorac Cardiovasc Surg ; 53(1): 1-8, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15692911

ABSTRACT

BACKGROUND: Tumours of the heart are rare. Different histological subtypes are known. The most common tumour entity is benign cardiac myxoma. Malignant heart tumours are less common. Tumours originating in other organs such as the kidney may also affect the heart by tumour progression via the inferior caval vein. A large experience with surgical treatment of different types of heart tumours is presented. METHODS: Between January 1989 and April 2004, 108 patients with a heart tumour were included in a database. All patients underwent radical surgical resection, except for 2 patients who had malignant lymphoma of the heart. RESULTS: Histological findings included 78 myxomas (72.2 %), and 6 other benign cardiac tumours in 5.6 % of the patients. Primary malignant heart tumours were seen in 10 (9.2 %) and renal cell carcinoma with cardiac involvement in 6 (5.6 %) patients. Eight patients presented with tumour metastases inside the heart (7.4 %). Mean overall survival was 12.7 years for myxoma patients and 5.6 years for patients with other benign heart tumours. Patients with primary malignant heart tumours survived 5.5 years on average. CONCLUSIONS: Heart tumours are rare, but usually life-threatening. Radical surgical resection is the therapy of choice and may offer excellent long-term survival, even in cases with malignant heart tumours.


Subject(s)
Cardiac Surgical Procedures/methods , Heart Neoplasms/surgery , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/secondary , Carcinoma, Renal Cell/surgery , Cardiac Surgical Procedures/mortality , Child , Child, Preschool , Female , Heart Neoplasms/mortality , Heart Neoplasms/secondary , Heart Transplantation , Humans , Infant , Infant, Newborn , Kidney Neoplasms/pathology , Male , Middle Aged , Myxoma/mortality , Myxoma/surgery , Survival Analysis , Vena Cava, Inferior/pathology
10.
Eur J Cardiothorac Surg ; 26(4): 730-5, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15450564

ABSTRACT

OBJECTIVE: Ventricular assist devices are increasingly used to treat patients with acute or chronic end-stage heart failure. We report on circumstances, exemplified on four cases, where a surprisingly favorable clinical course of the patients ultimately demanded early explantation of the device, which was not anticipated prior to its implantation. METHODS: The four patients were provided with implantable (Micromed BeBakey trade mark, Incor trade mark ) and external pneumatically driven (Thoratec trade mark, Excor trade mark ) devices under emergency conditions and were listed for heart transplantation. RESULTS: All four patients had an unexpected recovery of myocardial pump function. After careful diagnostic evaluation, all device components were completely removed without extracorporeal circulation. No stepwise weaning protocol was employed. CONCLUSIONS: Weaning patients from ventricular assist devices after recovery of myocardial pump function can become necessary. Diagnostic evaluation and the implementation of a weaning protocol is still a matter of debate, while complete surgical removal of all device components without extracorporeal circulation is possible with a low risk.


Subject(s)
Device Removal/methods , Heart Failure/therapy , Heart-Assist Devices , Acute Disease , Adolescent , Adult , Cardiomyopathy, Dilated/therapy , Cerebral Hemorrhage/etiology , Female , Graft Rejection , Heart Transplantation , Heart-Assist Devices/adverse effects , Humans , Male , Myocardial Infarction/therapy
11.
Thorac Cardiovasc Surg ; 52(4): 249-51, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15293164

ABSTRACT

We report on a 42-year-old patient with known dilative cardiomyopathy who underwent placement of a multiple transvenous pacemaker and ICD electrodes, and required removal of all leads via median sternotomy, followed by placement of epicardial electrodes. This experience has led us to question the necessity of the current implantation policies for these systems.


Subject(s)
Arrhythmias, Cardiac/therapy , Defibrillators, Implantable/adverse effects , Device Removal/methods , Postoperative Complications , Thoracic Surgical Procedures/methods , Adult , Arrhythmias, Cardiac/etiology , Cardiac Pacing, Artificial/adverse effects , Cardiomyopathy, Dilated/complications , Equipment Failure , Female , Humans , Reoperation
12.
Thorac Cardiovasc Surg ; 52(3): 163-8, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15192777

ABSTRACT

UNLABELLED: This study was designed to gain initial experience with rapamycin in thoracic organ transplant recipients with severely compromised kidney function, i.e. to see whether and how kidney function will improve with a rapamycin-based immunosuppressive protocol. METHODS: Twelve heart transplant patients were included into the study (serum creatinine > 2.5 mg/dL), with an average time after transplantation of more than 4 years. The calcineurin inhibitor (cyclosporine A = 9, tacrolimus = 3) was reduced by 50 %, and rapamycin added to reach a target level of 8 - 12 ng/dL. Azathioprine was halted, corticosteroid treatment remained unchanged. RESULTS: After implementing the rapamycin-based immunosuppression kidney function improved in all patients within one week. Serum creatinine dropped from 3.1 +/- 0.6 mg/dL to 2.7 +/- 0.5 mg/dL ( p = 0.0004), creatinine clearance increased from 30.4 +/- 11 mL/min to 40.8 +/- 10.5 mL/min ( p = 0.003). This improvement continued until 3 months after the conversion ( p = 0.032). Thereafter, no statistically significant changes were noted up to 6 months posttransplant ( p = 0.41). Serum cyclosporine levels dropped from 180 +/- 40 ng/mL to 132 +/- 46 ng/mL on average ( p = 0.002). Side-effects occurred in 4 patients and were all related to a rapamycin level exceeding 12 ng/mL. CONCLUSIONS: We conclude that transplant patients with impaired kidney function will have an immediate benefit from partially replacing calcineurin inhibitors by rapamycin.


Subject(s)
Heart Transplantation/immunology , Immunosuppressive Agents/therapeutic use , Kidney/drug effects , Sirolimus/therapeutic use , Aged , Creatinine/blood , Female , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/pharmacology , Kidney/physiopathology , Kidney Function Tests , Male , Middle Aged , Postoperative Period , Prospective Studies , Sirolimus/administration & dosage , Sirolimus/pharmacology
13.
Z Kardiol ; 92(7): 581-94, 2003 Jul.
Article in German | MEDLINE | ID: mdl-12883843

ABSTRACT

About three years ago, the German Government initiated a complete change in the reimbursement system for costs of the in-hospital treatment of patients. A commission of representatives from every component of the German health system decided to adapt the Australian refined Diagnosis Related Groups (AR-DRG system). The AR-DRG system was selected as it would fit best to the German system and because of its high flexibility and preciseness reflecting severity of diseases and treatments. In October 2002, the first German Diagnosis Related Groups (G-DRGs) were calculated from the data of about 116 hospitals. These data now allow first analyses in how far a correct and precise grouping of patients in specific hospital settings is indeed performed and corresponds to the actual costs. Thus, we thoroughly calculated all costs for material and personnel during the in-hospital stay for each patient discharged during the first 4 months of 2002 from our cardiological department. After performing the grouping procedure for each patient, we analyzed in how far inhomogeneous patient distribution in the DRGs occurred and which impact this had on costs and potential reimbursements. Several different problems were identified which should be outlined in this work regarding three G-DRGs: costs of patients who received an implantable cardioverter defibrillator (F01Z) were markedly influenced by multimorbidity and additional expensive interventions which were not reflected by this G-DRG. Use of numerous catheters and expensive drugs represented a major factor for costs in patients with coronary angioplasty in acute myocardial infarction (F10Z) but seemed to be not sufficiently included in the cost weight. A specific area of patient management in our department is high frequency ablation of tachyarrhythmias which is included in other percutaneous interventions (F19Z). Complex procedures such as ablation of ventricular tachycardia or new innovative procedures as ablation of atrial fibrillation were associated with high costs leading to inadequate reimbursement. Furthermore, problems in the associated codes for diseases and procedures became apparent. Opportunities for future optimization such as specific new DRGs, splitting of DRGs, or the impact of changes in reimbursement for high-outliers were discussed.


Subject(s)
Diagnosis-Related Groups/classification , Heart Diseases/classification , Hospital Charges/classification , National Health Programs/economics , Prospective Payment System/classification , Angioplasty, Balloon/classification , Angioplasty, Balloon/economics , Atrial Fibrillation/classification , Atrial Fibrillation/economics , Atrial Fibrillation/therapy , Cardiac Catheterization/classification , Cardiac Catheterization/economics , Cost-Benefit Analysis/statistics & numerical data , Costs and Cost Analysis , Defibrillators, Implantable/classification , Defibrillators, Implantable/economics , Diagnosis-Related Groups/economics , Germany , Heart Diseases/economics , Heart Diseases/therapy , Hospital Charges/statistics & numerical data , Humans , Length of Stay/economics , Length of Stay/statistics & numerical data , Mathematical Computing , Myocardial Infarction/classification , Myocardial Infarction/economics , Myocardial Infarction/therapy , Prospective Payment System/economics , Retrospective Studies , Tachycardia/classification , Tachycardia/economics , Tachycardia/therapy
14.
Thorac Cardiovasc Surg ; 50(6): 351-4, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12457312

ABSTRACT

BACKGROUND: Mitral valve surgery for the correction of secondary mitral valve regurgitation (MR) in cardiomyopathy is associated with a poor outcome. Numerous studies have identified a severe left ventricular dysfunction as an indicator for a poor prognosis. The aim of the study was to asses the follow-up after mitral valve surgery and severe left ventricular dysfunction. METHODS: Between 1994 and 2000, 31 patients with mitral regurgitation and a left ventricular ejection fraction of below thirty percent undergoing isolated repair (n = 16) or replacement (n = 15) were investigated. All patients received maximal drug therapy. Twenty-one patients were New York Heart Association (NYHA) class III and 10 were class IV. Follow-up with echocardiography, ECG, and chest x-ray was performed in 87 % of the survivors. The mean duration of follow-up was 39 +/- 16 months. RESULTS: The mean duration of ICU and hospital stay was 3.6 +/- 2.1 days and 8.1 +/- 5.4 days, respectively. The 1-, 2-, and 5-year survival rates were 91 %, 84 %, and 77 %, respectively. NYHA class improved from 3.3 +/- 0.8 to 2.1 +/- 0.7 at follow-up (p < 0.01). The ejection fraction improved from 23.1 +/- 6.6 % to 36 +/- 6.8 % at follow-up (p < 0.02). Freedom from readmission for heart failure was 85 %, 79 %, and 68 % at 1-, 2-, and 5 years, respectively. CONCLUSIONS: Mitral valve surgery improves left ventricular function and reduces heart failure severity in patients with MR and cardiomyopathy. High-risk mitral valve surgery may be an alternative to heart transplantation in selected patients.


Subject(s)
Mitral Valve Insufficiency/complications , Mitral Valve Insufficiency/surgery , Ventricular Dysfunction, Left/complications , Atrial Fibrillation/etiology , Coronary Artery Bypass , Female , Heart Valve Prosthesis , Humans , Intra-Aortic Balloon Pumping , Male , Middle Aged , Mitral Valve Insufficiency/physiopathology , Postoperative Complications/mortality , Prognosis , Risk Factors , Stroke Volume/physiology , Survival Rate , Ventricular Dysfunction, Left/physiopathology
15.
Thorac Cardiovasc Surg ; 50(1): 59-61, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11847607

ABSTRACT

Abstract. In this communication, we will present a very rare case of the coexistence of non-Hodgkin's lymphoma (NHL; low malignant lymphocytic lymphoma of the B-cell type) and a non-small-cell lung carcinoma (NSCLC). A patient with a 15-year history of NHL developed a generalized relapse of the lymphoma with an additional tumor mass in the left lower lobe of the lung. Bronchoscopy showed the evidence of the NHL. Due to non-responding chemotherapy on the lung tumor, the coexistence of a second malignancy was histologically proved in a second bronchoscopy. Resection of the lung tumor with complex lobectomy and lymphadenectomy was performed. After that, chemotherapy with four cycles of carboplatin supplemented with taxol was induced. The patient was discharged from the hospital with a stable remission of both tumor diseases. Restaging after six months showed no evidence of a tumor relapse. This is a very rare case of the coexistence of NHL and NSCLC; we will discuss the difficulty of diagnostic and treatment of both tumor diseases.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Lymphoma, Non-Hodgkin , Neoplasms, Second Primary , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bronchoscopy , Carboplatin/administration & dosage , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lymphoma, Non-Hodgkin/diagnostic imaging , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/pathology , Male , Neoplasms, Second Primary/diagnostic imaging , Neoplasms, Second Primary/drug therapy , Neoplasms, Second Primary/pathology , Paclitaxel/administration & dosage , Radiography
16.
Thorac Cardiovasc Surg ; 49(5): 306-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11605143

ABSTRACT

This paper describes a rare case of primary pigmented malignant schwannoma arising from the sympathetic trunk in the posterior mediastinum. A 30-year-old woman underwent a thoracoscopic tumor extirpation. A primary pigmented malignant schwannoma was diagnosed histologically. The tumor presented fascicles and whorls of pigmented plump spindle cells and positive immunoreactivity to S-100 protein, vimentin, and HMB-45. Postoperative radiotherapy of the mediastinum was performed. Our case demonstrates the successful thoracoscopic resection and postoperative radiation treatment of a malignant schwannoma.


Subject(s)
Mediastinal Neoplasms/radiotherapy , Mediastinal Neoplasms/surgery , Neurilemmoma/radiotherapy , Neurilemmoma/surgery , Pigmentation , Adult , Female , Humans , Mediastinal Neoplasms/pathology , Neurilemmoma/pathology
17.
Thorac Cardiovasc Surg ; 49(4): 204-9, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11505315

ABSTRACT

BACKGROUND: Tissue engineering is a promising approach for obtaining lifetime durability in biological heart valves. Basic questions with respect to the selection of suitable cell populations as well as scaffolds remain unsolved. The purpose of this study was to develop a tissue-like substitute in vitro for replacement of diseased valves in vivo. METHODS: Smooth-muscle cells (SMCs) were isolated from human and porcine aortic tissue using the 'explant technique' and endothelial cells from collagenase digestion. Seeding and cultivation of isolated cells was performed on a type-I collagen matrix. The scaffold-cell specimen was investigated using light and electron microscopy. Cupromeronic blue and immunoprecipitation were used for ultracytochemical staining. RESULTS: SMCs were allowed to grow to multilayers and migrate into the collagen network. We found a tissue-like morphology in these samples characterised by several layers of cells, spaces between the cell layers filled with newly formed extracellular matrix components, compartmentalisation of proteoglycans and their association with fibrilar matrix and the cell surface. Endothelium cells covered the SMCs of the scaffold with a histological topography similar to heart valves. CONCLUSIONS: This is an approach for in vitro modelling of tissue-like substitutes and preparing plane multicellular tissues as substitutes for heart valves. This model may also be used for cell biological investigations of cell-matrix interactions.


Subject(s)
Bioprosthesis , Collagen/ultrastructure , Endothelium, Vascular/cytology , Heart Valve Prosthesis , Models, Cardiovascular , Muscle, Smooth, Vascular/cytology , Animals , Cell Movement/physiology , Extracellular Matrix/ultrastructure , Humans , Microscopy, Electron , Prosthesis Design , Swine
18.
J Am Coll Cardiol ; 38(1): 124-30, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11451261

ABSTRACT

OBJECTIVES: We hypothesized that a temporary cardiopulmonary bypass (CPB)-induced reduction of endotoxin antibody levels contributes to elevated endotoxin levels and the associated inflammatory consequences, with a significant influence on the postoperative ventilation time period. BACKGROUND: Cardiac surgery using CPB induces a systemic inflammatory response syndrome with an associated risk of increased postoperative morbidity and mortality. METHODS: A total of 100 consecutive patients undergoing elective coronary artery bypass graft surgery using CPB were prospectively investigated. Endotoxin core antibodies (immunoglobulin [Ig] M/IgG against lipid A and lipopolysaccharide), endotoxin, interleukin (IL)-1-beta, IL-6, IL-8 and tumor necrosis factor-alpha were measured serially from 24 h preoperatively until 72 h postoperatively. RESULTS: Eighty-five patients had no complications (group 1), whereas 15 patients required prolonged ventilation (group 2). In both groups, there was a decrease of all antibodies 5 min after CPB onset, compared with baseline values (p < 0.001), an increase of endotoxin and IL-8 peaking at 30 min postoperatively (p < 0.001) and an increase of IL-6 peaking 3 h postoperatively (p < 0.001). In group 2, preoperative antibody levels were lower (p < 0.01)--specifically, the decrease in IgM was significantly stronger and of longer duration (p < 0.002)--and levels of endotoxin (p < 0.001) and IL-8 (p < 0.001) were higher at 30 min postoperatively. CONCLUSIONS: We conclude that an CPB-associated temporary reduction of anti-endotoxin core antibody levels contributes to elevated endotoxin and IL-8 release. Furthermore, lower levels of IgM anti-endotoxin core antibodies were associated with a greater rise in endotoxin and IL-8, as well as prolonged respirator dependence.


Subject(s)
Cardiopulmonary Bypass , Coronary Artery Bypass , Cytokines/blood , Endotoxins/blood , Immunoglobulin G/blood , Immunoglobulins/blood , Respiration, Artificial , Adult , Aged , Female , Humans , Interleukin-6/blood , Interleukin-8/blood , Male , Middle Aged , Prospective Studies , Time Factors
19.
Arch Gerontol Geriatr ; 32(3): 295-304, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11395175

ABSTRACT

A continuing increase in the number of very elderly patients with symptomatic heart disease referred for cardiac surgery has been observed in the past. Since 1990 all patients of 80 years and above have been included in a prospective study. We report on the results of the first 200 consecutive patients (mean age: 82.2+/-2.1 years). Operative procedures ranged from isolated myocardial revascularization and valve replacement to very complex operations. In a majority of patients, the operations had to be performed as urgent or emergency cases because of advanced heart disease. Overall 30 day mortality was 9.5%. More than two thirds of patients needed treatment of perioperative complications. During long-term follow-up, cardiac surgery in octogenarians has proved to be very effective with excellent functional status and quality of life. Because of favorable results elderly patients should not be denied the benefits of cardiac surgery requiring utilization of significant medical resources.

SELECTION OF CITATIONS
SEARCH DETAIL
...